Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis

Investigator: Ericka Greene, MD

Study Coordinator:

Status: Enrolling

ClinicalTrials.gov Number: NCT02301624

Phone:

Protocol Number: Pro00021711

Description

The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab for the treatment of participants with generalized myasthenia gravis (gMG). [NCT03920293]
More to Explore